Liu et al. found that IL-2 promotes the proliferation and activation of CD8 T cells during early-stage tumor development and induces the failure of CD8 T cells through the IL-2/STAT5 pathway during late-stage development [32]. The gene discussed is CD8A; the disease is neoplasm.